Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
1.990
-0.040 (-1.97%)
At close: Jul 25, 2025, 4:00 PM
2.099
+0.109 (5.48%)
After-hours: Jul 25, 2025, 7:59 PM EDT
Scienture Holdings Revenue
Scienture Holdings had revenue of $10.26K in the quarter ending March 31, 2025, a decrease of -92.03%. This brings the company's revenue in the last twelve months to $146.90K, down -84.76% year-over-year. In the year 2024, Scienture Holdings had annual revenue of $136.64K, down -89.98%.
Revenue (ttm)
$146.90K
Revenue Growth
-84.76%
P/S Ratio
74.13
Revenue / Employee
$7,732
Employees
19
Market Cap
26.10M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 136.64K | -1.23M | -89.98% |
Dec 31, 2023 | 1.36M | 1.06M | 354.61% |
Dec 31, 2022 | 300.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSCNX News
- 2 days ago - Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding - GlobeNewsWire
- 10 days ago - Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 5 weeks ago - Scienture Holdings Announces Cancelation of ELOC - GlobeNewsWire
- 2 months ago - Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value - Accesswire
- 2 months ago - SCIENTURE Announces Executive Leadership Transition - GlobeNewsWire
- 2 months ago - SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL. - GlobeNewsWire
- 3 months ago - SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. - GlobeNewsWire
- 3 months ago - SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC. - GlobeNewsWire